Latham Advises Rhythm on Agreement to Acquire Global Rights to Oral MC4R Agonist LB54640 From LG Chem

Latham & Watkins has advised Rhythm Pharmaceuticals, Inc. (Rhythm), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, on its global licensing agreement with LG Chem Life Sciences (LG Chem), a Korean life sciences company, for LB54640, an investigational oral small molecule melanocortin-4 receptor (MC4R) agonist now in Phase 2 clinical trials.

The Latham licensing team was led by partner Steven Chinowsky with associates Oliver Mobasser and Ami Sodha. The corporate team was led by partners Peter Handrinos and Elizabeth Mims Slawsby. Advice was also provided on antitrust matters by partners Mandy Reeves and Hector Armengod, with counsel Patrick English; on public company matters by partners Jennifer Yoon and Jenna Cooper, with associates Hamna Ahmad and Naseem Faqihi Alawadhi; on tax matters by partner Kirt Switzer and associate Derek Gumm; and on patent diligence by counsel Darryl Steensma.